What's New at Charles River
   
 
 
   
   

Charles River Acquires Cerebricon LTD

August 4, 2009 – Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Cerebricon Ltd. Cerebricon, located in Kuopio, Finland, brings together MRI (magnetic resonance imaging) techniques, biomarkers and behavioral measurements in gold standard assays for acute neurology (such as stroke and spinal cord injury), chronic neurology (including multiple sclerosis and Alzheimer’s and Parkinson’s disease) and psychiatry (exemplified by ADHD, schizophrenia and depression).

Through our Discovery and Imaging Services group, which includes MIR Preclinical Services (acquired in 2008) and Piedmont Research Center (acquired in 2009), we have established ourselves as a premier provider of non-GLP pharmacology and in vivo imaging services for the evaluation of compound efficacy. Our therapeutic areas of expertise now span oncology, cardiovascular, metabolism, inflammation and CNS, all of which are areas of increasing R&D focus.

For more information, please call 1.877.CRIVER.1 (1.877.274.8371) or email us at askcharlesriver@crl.com.

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
May 08 - Access Xenograft Data for Immunode...
May 01 - New GEMS Webinars Now Available On...
Jun 02-Jun 05 - Vancouver, British Columbia - CALAS
Jun 18-Jun 21 - Newton, MA - 2012 Charles River Short Course on Laboratory Animal Scien...
Jun 05-Jun 08 - Saint Germain sur l’Arbresle, France - Charles River LAL Seminar Series
view all
Scientist I Wilmington, MA
Manager International Tax Wilmington, MA

Charles River Laboratories, Inc.